NCT01351675View on ClinicalTrials.gov

Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes

PHASE3TerminatedINTERVENTIONAL
Enrollment

2,185

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

December 31, 2012

Conditions
Renal Insufficiency, ChronicDiabetes Mellitus, Type 2
Interventions
DRUG

Placebo

Oral, once daily

DRUG

Bardoxolone Methyl: 20 mg

20 mg, oral, once daily

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT01351675 - Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes | Biotech Hunter | Biotech Hunter